Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.59 |
| ▸ | FAAH | O00519 | 3/20 | 0.58 |
| ▸ | CES1 | P23141 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7768077 | 0.98 | MAPT (0.71) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL7883758 | 0.98 | MAPT (0.71) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL9664667 | 0.98 | MAPT (0.71) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL3250759 | 0.98 | MAPT (0.71) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL5793035 | 0.98 | MAPT (0.71) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL9664005 | 0.98 | MAPT (0.71) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL3253249 | 0.98 | MAPT (0.71) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL61491 | 0.94 | HDAC1 (0.69) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL8772423 | 0.93 | MAPT (0.82) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL27538484 | 0.92 | HDAC1 (0.67) | MAPTRXFP1HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250009285-A1 | PRE-SEIZURE DETECTION DEVICE INCORPORATING ELECTRONIC NOSE TECHNOLOGY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2025-01-09 | — | — | US | claimed |
| US-4272502-A | Process for preparing gaseous hydrogen chloride from dilute aqueous hydrochloric acid | CHEMISCHE WERKE HULS AKTIENGESELLSCHAFT (DE) | 1981-06-09 | — | — | US | claimed |
| EP-4692061-A1 | LOW-MOLECULAR-WEIGHT COMPOUND HAVING CEREBLON-BINDING ACTIVITY, AND USE THEREOF | Aevis Bio, Inc. (KR) | 2026-02-11 | — | — | EP | disclosed |
| US-20250288559-A1 | PREP BINDING LIGANDS | POLKU THERAPEUTICS OY (FI) | 2025-09-18 | — | — | US | disclosed |
| EP-4514781-A1 | PREP BINDING LIGANDS | Polku Therapeutics OY (FI) | 2025-03-05 | — | — | EP | disclosed |
| CN-119451944-A | PREP binding ligands | 珀尔库治疗有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20250009285-A1 | PRE-SEIZURE DETECTION DEVICE INCORPORATING ELECTRONIC NOSE TECHNOLOGY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2025-01-09 | — | — | US | disclosed |
| WO-2024205319-A1 | LOW-MOLECULAR-WEIGHT COMPOUND HAVING CEREBLON-BINDING ACTIVITY, AND USE THEREOF | 주식회사 아이비스바이오 | 2024-10-03 | — | — | WO | disclosed |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230364272-A1 | THERANOSTIC COMPOUNDS | UNIVERSITY OF CAPE TOWN (ZA) | 2023-11-16 | — | — | US | disclosed |
| US-20230364272-A1 | THERANOSTIC COMPOUNDS | UNIVERSITY OF CAPE TOWN (ZA) | 2023-11-16 | — | — | US | disclosed |
| EP-0273451-A2 | Lipoxygenase inhibitory compounds | Bristol-Myers Squibb Company (US) | 1988-07-06 | — | — | EP | disclosed |
| US-4705802-A | Omega-aryl-alkylthienyl-compounds and process for the treatment of chronically inflammatory processes in humans | A. NATTERMANN & CIE GMBH (DE) | 1987-11-10 | — | — | US | disclosed |
| EP-0201741-A2 | Dipeptide derivatives, processes for preparing them, pharmaceutical composition and use | SUNTORY LIMITED (JP) | 1986-11-20 | — | — | EP | disclosed |
| EP-0155524-A1 | -Omega-aryl-alkylthienyl compounds, process for their preparation and pharmaceutical products containing these compounds | A. Nattermann & Cie. GmbH (DE) | 1985-09-25 | — | — | EP | disclosed |
| US-4272502-A | Process for preparing gaseous hydrogen chloride from dilute aqueous hydrochloric acid | CHEMISCHE WERKE HULS AKTIENGESELLSCHAFT (DE) | 1981-06-09 | — | — | US | disclosed |
| EP-0019699-A1 | Process for the production of gaseous hydrogen chloride from dilute aqueous hydrochloric acid | CHEMISCHE WERKE HÜLS AG (DE) | 1980-12-10 | — | — | EP | disclosed |
| EP-0014386-A2 | Phosphoramido(di)thioate derivatives, processes for their preparation and pesticidal compositions containing them, as well as intermediates | ROHM AND HAAS COMPANY (US) | 1980-08-20 | — | — | EP | disclosed |
| US-3992396-A | TRANQUILIZERS, HYPNOTICS | SANDOZ, INC. (US) | 1976-11-16 | — | — | US | disclosed |
| US-3984501-A | PROSTAGLANDIN INHIBITORS | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364272-A1 | THERANOSTIC COMPOUNDS | MMP12, TIMP3, CTSZ | MAPT 689/4885RXFP1 1884/4885HDAC1 125/4885 |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | MAPT 3228/4885RXFP1 239/4885HDAC1 4258/4885 |
| US-20250288559-A1 | PREP BINDING LIGANDS | PREP, ERAP2, CTSA | MAPT 326/4885RXFP1 3141/4885HDAC1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.